Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Summary

This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas.

Timeline

Start

2025-05-21

Primary completion

2027-05-31

Completion

2027-05-31

Publications

• Wu BX, Kreatsoulas D, Cam H, Bolyard C, Chang Y, Mandula J, Welsh PW, Wang Z, Li A, Weltge P, Reynolds K, Amankwah Y, Elder JB, Giglio P, Otero JJ, Rajappa P, Gerald D, Chung D, Ma Q, Velegraki M, Li Z. Targeting TGFbeta docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma. Neuro Oncol. 2025 Dec 1;27(12):3087-3103. doi: 10.1093/neuonc/noaf195.

Drugs

Indications